Norges Bank
LGND icon

Norges Bank’s Ligand Pharmaceuticals LGND Stock Holding History

Norges Bank’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-14,073
Closed -$1.6M – 860
2025
Q2 		$1.6M Sell
14,073
-9,021
-39% -$964K ﹤0.01% 1464
2025
Q1 		$2.43M Sell
23,094
-23,196
-50% -$2.62M ﹤0.01% 1492
2024
Q4 		$4.96M Sell
46,290
-10,760
-19% -$1.22M ﹤0.01% 1505
2024
Q3 		$5.71M Sell
57,050
-18,144
-24% -$1.83M ﹤0.01% 1495
2024
Q2 		$6.34M Sell
75,194
-16,447
-18% -$1.31M ﹤0.01% 1503
2024
Q1 		$6.7M Sell
91,641
-15,547
-15% -$1.15M ﹤0.01% 1563
2023
Q4 		$7.66M Sell
107,188
-30,800
-22% -$1.82M ﹤0.01% 1577
2023
Q3 		$8.27M Buy
137,988
+32,511
+31% +$2.14M ﹤0.01% 1540
2023
Q2 		$7.6M Sell
105,477
-26,700
-20% -$2M ﹤0.01% 1615
2023
Q1 		$9.72M Sell
132,177
-12,890
-9% -$916K ﹤0.01% 1595
2022
Q4 		$9.69M Sell
145,067
-58,942
-29% -$3.83M ﹤0.01% 1583
2022
Q3 		$11M Buy
204,009
+8,807
+5% +$518K ﹤0.01% 1499
2022
Q2 		$10.9M Sell
195,202
-6,906
-3% -$392K ﹤0.01% 1526
2022
Q1 		$14.2M Buy
202,108
+5,811
+3% +$422K ﹤0.01% 1563
2021
Q4 		$18.9M Buy
196,297
+42,746
+28% +$3.95M ﹤0.01% 1510
2021
Q3 		$13.3M Buy
153,551
+66,167
+76% +$5.12M ﹤0.01% 1668
2021
Q2 		$7.15M Sell
87,384
-97,107
-53% -$8.08M ﹤0.01% 1844
2021
Q1 		$17.5M Sell
184,491
-31,440
-15% -$2.97M ﹤0.01% 1604
2020
Q4 		$13.4M Sell
215,931
-1,376
-0.6% -$78.4K ﹤0.01% 1694
2020
Q3 		$12.9M Sell
217,307
-75,693
-26% -$5.16M ﹤0.01% 1635
2020
Q2 		$20.4M Sell
293,000
-47,607
-14% -$3.02M 0.01% 1407
2020
Q1 		$15.5M Sell
340,607
-22,840
-6% -$1.29M 0.01% 1413
2019
Q4 		$23.6M Sell
363,447
-14,439
-4% -$965K 0.01% 1436
2019
Q3 		$23.5M Hold
377,886
– – 0.01% 1391
2019
Q2 		$26.9M Hold
377,886
– – 0.01% 1302
2019
Q1 		$29.6M Hold
377,886
– – 0.01% 1217
2018
Q4 		$32M Buy
377,886
+20,864
+6% +$2.22M 0.01% 1077
2018
Q3 		$61.1M Buy
357,022
+22,878
+7% +$3.45M 0.02% 723
2018
Q2 		$43.2M Buy
334,144
+19,929
+6% +$2.22M 0.01% 955
2018
Q1 		$32.4M Buy
314,215
+31,899
+11% +$3.15M 0.01% 1088
2017
Q4 		$24.1M Buy
282,316
+29,739
+12% +$2.58M 0.01% 1348
2017
Q3 		$21.5M Hold
252,577
– – 0.01% 1397
2017
Q2 		$19.1M Buy
252,577
+5,693
+2% +$398K 0.01% 1441
2017
Q1 		$16.3M Sell
246,884
-60,743
-20% -$4M 0.01% 1517
2016
Q4 		$19.5M Hold
307,627
– – 0.01% 1323
2016
Q3 		$18.7M Buy
307,627
+21,387
+7% +$1.57M 0.01% 1284
2016
Q2 		$21.3M Buy
286,240
+39,114
+16% +$2.9M 0.01% 1164
2016
Q1 		$16.5M Hold
247,126
– – 0.01% 1278
2015
Q4 		$16.7M Hold
247,126
– – 0.01% 1281
2015
Q3 		$13.2M Buy
247,126
+147,072
+147% +$8.92M 0.01% 1395
2015
Q2 		$6.3M Buy
100,054
+38,270
+62% +$2.09M ﹤0.01% 1832
2015
Q1 		$2.97M Hold
61,784
– – ﹤0.01% 2011
2014
Q4 		$2.05M Buy
+61,784
New +$2.01M ﹤0.01% 2096

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Norges Bank's LGND Position: Q3 2025 in Review

Norges Bank sold out of Ligand Pharmaceuticals (LGND) in Q3 2025, closing a stake of 14,073 shares — an estimated $1.6M sold.

Norges Bank first reported a position in LGND in Q4 2014 and held it in 43 quarters. The position peaked at $61.1M in Q3 2018. 314 funds tracked by Wall St. Rank hold LGND as of Q3 2025.

  • Norges Bank reported no remaining Ligand Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Norges Bank sold 14,073 Ligand Pharmaceuticals shares in Q3 2025, an estimated $1.6M.
  • Norges Bank first reported a position in Ligand Pharmaceuticals in Q4 2014 and held it in 43 quarters.
  • Norges Bank's Ligand Pharmaceuticals position peaked at $61.1M in Q3 2018.
  • 314 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2025.

Based on Norges Bank's 13F filing for Q3 2025.